Designing and analyzing clinical trials with composite outcomes: Consideration of possible treatment differences between the individual outcomes

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Pogue, Janice ^a   Devereaux, P J ^a   Thabane, Lehana ^a   Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO;

ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL (TOPIC); COMPOSITE OUTCOME; DEATH; HAZARD RATIO; HEART ARREST; HEART INFARCTION; METHODOLOGY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

BIOMEDICAL RESEARCH; HUMANS; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84859840957     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034785     Document Type: Article

References (32)

1. DeMets D, Califf R, (2002) Lessons learned from recent cardiovascular clinical trials: Part I. Circulation 106: 746-751.
2. Ferreira-Gonzalez I, Busse J, Heels-Ansdell D, Montori V, Akl E, et al. (2007) Problems with use of composite end points in cardiovascular trials: Systematic review of randomized controlled trials. British Medical Journal.
3. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C, (2003) Composite outcomes in randomized trials: Greater precision but with greater uncertainty? Journal of the American Medical Association 289: 2254-2259.
4. Montori V, Permanyer-Miralda G, Ferreira-Gonzalez I, Busse J, Pacheco-Huergo et al, (2005) Validity of composite outcomes in clinical trials. British Medical Journal 330: 594-596.
5. Montori V, Busse J, Permanyer-Miralda G, Ferreira-Gonzalez I, Guyatt G, (2005) How should clinicians interpret results reflecting the effect of an intervention on composite endpoints: Should I dump this lump? ACP Journal Club 143: A8-A9.
6. Moye, LA, (2003) Multiple analyses in clinical trials. New York Springer.
7. Neaton J, Gray G, Zuckerman B, Konstam M, (2005) Key issues in end point selection from heart failure trials: Composite end points. Journal of Cardiac Failure 11: 567-575.
8. Huque M, Sankoh A, (1997) A reviewer's perspective on multiple endpoint issues in clinical trials. Journal of Biopharmaceutical Statistics 7: 545-564.
9. Chi G, (2005) Some issues with composite endpoints. Fundamental & Clinical Pharmacology 19: 609-619.
10. Sankoh A, D'Agostino R Sr, Huque M, (2003) Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues. Statistics in Medicine 22: 3133-3150.
11. Pocock S, Assmann S, Enos L, Kasten L, (2002) Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Statistics in Medicine 21: 2917-2930.
12. Yusuf S, Wittes J, Probstfield J, Tyroler H, (1991) Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Journal of the American Medical Association 93-98.
13. Petitti D, (2001) Approaches to heterogeneity in meta-analysis. Statistics in Medicine 20: 3625-3633.
14. Devereaux P, Yang H, Yusuf S, Guyatt G, Leslie K, et al. (2008) Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. The Lancet 371: 1839-1847.
15. McCullagh, P, Nelder, JA, (1989) Generalized Linear Models. London Chapman and Hall.
16. Liang K, Zeger S, (1986) Longitudinal data analysis using generalized linear models. Biometrika 73: 13-22.
17. Tilley B, Marler J, Geller N, Lu M, Legler J, et al. (1996) for the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Trial Study Group. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Trial. Stroke 27: 2136-2142.
18. Zeger S, Liang K, (1992) An overview of methods for the analysis of longitudinal data. Statistics in Medicine 11: 1825-1839.
19. Pogue J, Thabane L, Devereaux P, Yusuf S, (2010) Testing for heterogeneity among the components of a binary composite outcome in a clinical trial. BMC Medical Research Methodology 10.
20. Donald A, Donner A, (1987) Adjustment to the Mantel-Haenszel chi-squared statistic and odds ratio estimator when the data are clustered. Statistics in Medicine 6: 491-499.
21. Rao J, Scott A, (1992) A simple method for the analysis of clustered binary data. Biometrics 48: 577-585.
22. Duchateau L, Janssen, P, (2008) The Frailty Model. New York Springer Science.
23. Wei L, Lin D, Weissfeld L, (1989) Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. Journal of the American Statistical Association 84: 1065-1073.
24. Wei L, Glidden D, (1997) An overview of statistical methods for multiple failure time data in clinical trials. Statistics in Medicine 16: 833-839.
25. Pogue, J, (2012) Testing for treatment heterogeneity between the individual outcomes within a composite outcome [dissertation]. McMaster University.
26. Cox D, (1972) Regression models and life-tables. Journal of the Royal Statistical Society, Series B 34: 187-202.
27. Lin D, Wei L, (1992) Linear regression analysis for multivariate failure time observations. Journal of the American Statistical Association 87: 1091-1097.
28. R Development Core Team (2008) R A language and environment for statistical computing., version 2.11.1 [computer program]. Vienna, Austria R Foundation for Statistical Computing.
29. Burton A, Altman D, Royston P, Holder R, (2006) The design of simulation studies in medical statistics. Statistics in Medicine 25: 4279-4292.
30. Higgins J, Thompson S, Deeks J, Altman D, (2008) Measuring inconsistency in meta-analyses. British Medical Journal 327: 557-560.
31. Assman S, Pocock S, Enos L, Kasten L, (2000) Subgroup analysis and other (mis)uses of baseline data in clinical trials. The Lancet 355: 1064-1069.
32. Montgomery, DC, Peck, EA, (1982) Introduction to Linear Regression Analysis. New York John Wiley & Sons.